Yana Najjar
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Yana Najjar sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
Yana Najjar: 8 sponsored US clinical trials, 5 recruiting.
Yana Najjar sponsors 8 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Melanoma, with 4 trials.
Upper-quartile sponsor footprint
Yana Najjar sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
Evaluation of Hypoxia in Primary Melanoma
NCT06831071
RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis
NCT06216938
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
NCT04572451
Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma
NCT04658303
A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma
NCT03311308
Nivolumab Plus Axitinib in Patients With Anti-PD1 Refractory Advanced Melanoma
NCT04493203
Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma
NCT02818023
Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b
NCT02339324
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 1 |
What is open in the Yana Najjar pipeline
5 recruiting of 8 indexed (63% open); 2 completed (25%).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Melanoma (4 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Yana Najjar: open-pipeline peers nationwide
Peers matched on 8 registered trials and 63% open enrollment, not the therapeutic-area sidebar.
Yana Najjar sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 63% open enrollment (± trial volume)
- Canadian Cancer Trials Group · 63% recruiting · 16 trials
- CellSight Technologies · 63% recruiting · 8 trials
- Cook Children's Health Care System · 63% recruiting · 8 trials
- Nurix Therapeutics · 63% recruiting · 8 trials
Related
What to do with this Yana Najjar page
8 registered trials is a research-attention snapshot, not an endorsement of Yana Najjar or any single study.
- 5 of Yana Najjar's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Melanoma is the condition Yana Najjar studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Melanoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Yana Najjar pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.